uPAR PET/CT in Radium-223-dichloride Treatment of Patients With Metastatic Castration-resistant Prostate Cancer
Status:
Terminated
Trial end date:
2019-10-11
Target enrollment:
Participant gender:
Summary
The purpose of this study is to investigate the applicability of urokinase plasminogen
activator receptor (uPAR) Positron Emission Tomography (PET) / CT molecular imaging in
patients with metastatic castration-resistant prostate cancer (mCRPC)